Lynk Pharmaceuticals Completes Phase III Enrolment for Zemprocitinib in Ankylosing Spondylitis
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
Lynk Pharmaceuticals has completed phase III enrollment for a treatment, known as Zemprocitinib, which is being studied for ankylosing spondylitis. The treatment is described as an oral JAK1 inhibitor. Enrollment completion has been reported for this phase of the study.